OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company’s product pipeline includes KEYNOTE-695, which is i... OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company’s product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University’s Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey. On June 14, 2023, OncoSec Medical Incorporated filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of New Jersey. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 279 | 1.0E-6 | CS |
| 4 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 279 | 1.0E-6 | CS |
| 12 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 974 | 1.0E-6 | CS |
| 26 | 0 | 0 | 1.0E-6 | 0.0001 | 1.0E-6 | 2737 | 7.919E-5 | CS |
| 52 | 0 | 0 | 1.0E-6 | 0.0001 | 1.0E-6 | 13514 | 9.517E-5 | CS |
| 156 | -0.179999 | -99.9994444444 | 0.18 | 0.23 | 1.0E-6 | 39411 | 0.10203841 | CS |
| 260 | -0.179999 | -99.9994444444 | 0.18 | 0.23 | 1.0E-6 | 39411 | 0.10203841 | CS |
jacksonjohn
2年前
Refined Sugar Kills
2年前
splintered sunlight
3年前
trader59
3年前
hondaboost
3年前
Triple nickle
3年前
dbcoop1
3年前
Triple nickle
3年前
jacksonjohn
3年前
Triple nickle
3年前
Triple nickle
3年前
madras50
3年前
Awl416
3年前
Leave_the_gun
3年前
Jess070283
3年前
eur06
3年前
dinogreeves
3年前
dinogreeves
3年前
dinogreeves
3年前
dinogreeves
3年前
harry crumb
3年前
rx7171
3年前
harry crumb
3年前
carp77
3年前
jacksonjohn
3年前
Moonboy1
3年前
Arnold25764
3年前
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。